Research
Hormonal
Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.
Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.
StrongSupportsmedium confidence
Adding semaglutide to usual care in the estimated 4 million US adults without diabetes eligible for secondary prevention of CVD is projected to avert 358 400 MACE at a cost of $148 100 per QALY gained.
Why this rating
Based on a population-based cohort simulation study design.
Source
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Susan Hennessy et al. · JAMA Cardiology · 2026
cohort · n=4000000Cited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →